Please use this identifier to cite or link to this item: https://saber.ucv.ve/jspui/handle/10872/1711
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPonte-Sucre, Alicia-
dc.contributor.authorFigarella, Katherine-
dc.contributor.authorMoll, Heidrun-
dc.date.accessioned2012-08-28T14:35:02Z-
dc.date.available2012-08-28T14:35:02Z-
dc.date.issued2012-08-28-
dc.identifier.issn0892-3973-
dc.identifier.urihttp://hdl.handle.net/10872/1711-
dc.description.abstractPrevious studies from our laboratories revealed the susceptibility of Leishmania sp. to glibenclamide (GLIB), a potassium channel blocker which selectively interacts with adenosine-binding-cassette transporters. In the present work, we analyzed whether the drug sensitivity of intracellular amastigotes correlates with changes in macrophage features that are related to their function as antigen-presenting cells. We provide evidence that in BALB/c murine macrophages, GLIB induced a decrease in the interferon-gamma-stimulated expression of major histocompatibility complex class II molecules and the co-stimulatory molecule CD86 (B7-2). Furthermore, it caused a decrease in the interleukin-1 secretion by macrophages. The data indicate that the treatment with GLIB inhibits the Th2 development and polarizes macrophage functions towards the induction of a protective Th1 response.es_VE
dc.description.sponsorshipConsejo de Desarrollo Cientifico y Humanistico de la UCV, Fundacion Alejandro de Humboldt-Alemaniaes_VE
dc.language.isoen_USes_VE
dc.relation.ispartofseriesInmunopharmacology and Immunotoxicology;23: 477-486, 2001-
dc.subjectMacrophageses_VE
dc.subjectInfectivityes_VE
dc.subjectGlibenclamidees_VE
dc.titleExperimental Leishmaniasis: The glibenclamide-triggered decrease in parasite growth correlates with changes in macrophage features.es_VE
dc.typeArticlees_VE
Appears in Collections:Artículos Publicados

Files in This Item:
File Description SizeFormat 
Figarella et al.pdf128.88 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.